Suven Life Sciences Performance
- Today's Low
- ₹310
- Today's High
- ₹330
- 52 Week Low
- ₹124
- 52 Week High
- ₹336
- Open Price₹328
- Previous Close₹328
- Volume1,479,375
- 50 DMA₹251.34
- 100 DMA₹224.38
- 200 DMA₹204.50
Suven Life Sciences Chart
Investment Returns
- Over 1 Month + 32.5%
- Over 3 Month + 99.1%
- Over 6 Month + 94.23%
- Over 1 Year + 23.28%
Smart Investing Starts Here Start SIP with Suven Life Sciences for Steady Growth!
Suven Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -30
- PEG Ratio
- 0.4
- Market Cap Cr
- 8,303
- P/B Ratio
- 14
- Average True Range
- 18.47
- EPS
- 0
- Dividend Yield
- 0
- MACD Signal
- 10.22
- RSI
- 66.92
- MFI
- 70.26
Latest Stock News Updates
Clinical-stage biotech will present three posters highlighting Phase 2 results and Phase 3 plans for narcolepsy treatment.
- Business Line
- 3 weeks 3 days ago
Conducted entirely in the United States, the randomised, double-blind, placebo-controlled trial aims to evaluate the safety and efficacy of Ropanicant across 195 patients at 35 sites over six weeks.
- Business Line
- 6 months 3 weeks ago
Healthcare Services company Suven Life Sciences announced Q2FY26 results Revenue: Rs 46.97 million against Rs 66.09 million during Q2FY25. PAT: Rs -773.10 million against Rs -496.44 million during Q2FY25. EPS: Rs -3.48 for Q2FY26. Clinical development pipeline: SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer’s type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion by end of calander 2026. SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by end of fiscal 2026. SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA and expected completion by end of calander 2026. SUVN-D4010 (Usmarapride) – Planning for Phase 2 double blind study for the treatment of Cognition during 2026. SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics of the molecule. Anticipated completion by fiscal 2026. Result PDF
- Trendlyne
- 7 months 3 weeks ago
Suven Life Sciences Financials
Suven Life Sciences Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹277.30
- 50 Day
- ₹251.30
- 100 Day
- ₹224.40
- 200 Day
- ₹204.50
Resistance and Support
- R3 346.23
- R2 338.27
- R1 326.38
- S1 306.53
- S2 298.57
- S3 286.68
Suven Life Sciences Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-05-13 | Audited Results | |
| 2026-01-29 | Quarterly Results | |
| 2025-11-11 | Quarterly Results | |
| 2025-08-13 | Quarterly Results | |
| 2025-05-13 | Audited Results & Preferential issue |
About Suven Life Sciences
- NSE Symbol
- SUVEN
- BSE Symbol
- 530239
- Chairman & Managing Director
- Mr. Venkateswarlu Jasti
- ISIN
- INE495B01038
Similar Stocks to Suven Life Sciences
Popular Stocks
Suven Life Sciences FAQs
Suven Life Sciences share price is ₹314 As on 07 July, 2026 | 01:15
The Market Cap of Suven Life Sciences is ₹8302.6 Cr As on 07 July, 2026 | 01:15
The P/E ratio of Suven Life Sciences is -30 As on 07 July, 2026 | 01:15
The PB ratio of Suven Life Sciences is 14 As on 07 July, 2026 | 01:15
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.